GlassScriptPhysician profile
Dunia Rodriguez
NPI 1083923080
$3,702.36
in general payments reported to CMS, 2019-2025
9 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $447 · 2022: $839 · 2023: $1,036 · 2024: $938 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388 · Education: $29.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.73 |
| Education | $29.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,609.16 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $788.73 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $612.18 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $291.05 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $163.91 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Pfizer INC. | $129.74 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.13 | 2022-2024 | |
| Phadia US INC. | $20.86 | 2023 | Immunocap |
| Novartis Pharmaceuticals Corporation | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dunia Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.